{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:21:17Z","timestamp":1782980477842,"version":"3.54.5"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001656","name":"Helmholtz-Gemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011736","name":"Ministerium f\u00fcr Wirtschaft, Arbeit und Wohnungsbau Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011736","name":"Ministerium f\u00fcr Wirtschaft, Arbeit und Wohnungsbau Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recent increases in SARS-CoV-2 infections have led to questions about duration and quality of vaccine-induced immune protection. While numerous studies have been published on immune responses triggered by vaccination, these often focus on studying the impact of one or two immunisation schemes within subpopulations such as immunocompromised individuals or healthcare workers. To provide information on the duration and quality of vaccine-induced immune responses against SARS-CoV-2, we analyzed antibody titres against various SARS-CoV-2 antigens and ACE2 binding inhibition against SARS-CoV-2 wild-type and variants of concern in samples from a large German population-based seroprevalence study (MuSPAD) who had received all currently available immunisation schemes. We found that homologous mRNA-based or heterologous prime-boost vaccination produced significantly higher antibody responses than vector-based homologous vaccination. Ad26.CoV2S.2 performance was particularly concerning with reduced titres and 91.7% of samples classified as non-responsive for ACE2 binding inhibition, suggesting that recipients require a booster mRNA vaccination. While mRNA vaccination induced a higher ratio of RBD- and S1-targeting antibodies, vector-based vaccines resulted in an increased proportion of S2-targeting antibodies. Given the role of RBD- and S1-specific antibodies in neutralizing SARS-CoV-2, their relative over-representation after mRNA vaccination may explain why these vaccines have increased efficacy compared to vector-based formulations. Previously infected individuals had a robust immune response once vaccinated, regardless of which vaccine they received, which could aid future dose allocation should shortages arise for certain manufacturers. Overall, both titres and ACE2 binding inhibition peaked approximately 28 days post-second vaccination and then decreased.<\/jats:p>","DOI":"10.3389\/fimmu.2022.828053","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:42:29Z","timestamp":1644972149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany"],"prefix":"10.3389","volume":"13","author":[{"given":"Alex","family":"Dulovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Harries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Griesbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"J\u00fcngling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gornyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Gl\u00f6ckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Melhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Castell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana-Kristin","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Kemmling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Tonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Illig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Klopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Warikoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Suckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Ulrike","family":"Marzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Grupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp D.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Traenkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Rothbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kerrinnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Schneiderhan-Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Strengert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.Cov2.S Vaccine Against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","unstructured":""},{"key":"B6","year":"2021"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7037e1","article-title":"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021","volume":"70","author":"Scobie","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B8","unstructured":"2021"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1101\/2021.08.16.21262115","article-title":"Diminishing Immune Responses Against Variants of Concern in Dialysis Patients Four Months After SARS-CoV-2 mRNA Vaccination","volume-title":"medRxiv","author":"Dulovic","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01413-7","article-title":"Evidence for Increased Breakthrough Rates of SARS-CoV-2 Variants of Concern in BNT162b2-mRNA-Vaccinated Individuals","volume":"27","author":"Kustin","year":"2021","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of Antibody Response to BNT162b2 Vaccine After Six Months: A Longitudinal Prospective Study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Regional Health - Europe"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for Antibody as a Protective Correlate for COVID-19 Vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279000","article-title":"Antibody-Mediated Procoagulant Platelets in SARS-CoV-2-Vaccination Associated Immune Thrombotic Thrombocytopenia","volume":"106","author":"Althaus","year":"2021","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia After ChAdOx1 Ncov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"New Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1114","article-title":"Arterial Events, Venous Thromboembolism, Thrombocytopenia, and Bleeding After Vaccination With Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population Based Cohort Study","volume":"373","author":"Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"n699","DOI":"10.1136\/bmj.n699","article-title":"Covid-19: European Countries Suspend Use of Oxford-AstraZeneca Vaccine After Reports of Blood Clots","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.25646\/8467","article-title":"Beschluss Der STIKO Zur 5. Aktualisierung Der COVID-19-Impfempfehlung Und Die Dazugeh\u00f6rige Wissenschaftliche Begr\u00fcndung","author":"Vygen-Bonnet","year":"2021","journal-title":"Epid Bull"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and Reactogenicity of Heterologous ChAdOx1 Ncov-19\/mRNA Vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune Responses Against SARS-CoV-2 Variants After Heterologous and Homologous ChAdOx1 Ncov-19\/BNT162b2 Vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01854-7","article-title":"Neutralising Antibodies After COVID-19 Vaccination in UK Haemodialysis Patients","volume":"398","author":"Carr","year":"2021","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103524","article-title":"Cellular and Humoral Immunogenicity of a SARS-CoV-2 mRNA Vaccine in Patients on Haemodialysis","volume":"70","author":"Strengert","year":"2021","journal-title":"EBioMedicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"Doc15","DOI":"10.3205\/dgkh000386","article-title":"Symptoms, Antibody Levels and Vaccination Attitude After Asymptomatic to Moderate COVID-19 Infection in 200 Healthcare Workers","volume":"16","author":"Harsch","year":"2021","journal-title":"GMS Hygiene Infect Control"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1038\/s41467-021-23473-6","article-title":"Immune Response to SARS-CoV-2 Variants of Concern in Vaccinated Individuals","volume":"12","author":"Becker","year":"2021","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2020.11.008","article-title":"Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Healthcare Workers: A Systematic Review and Meta-Analysis","volume":"108","author":"Galanis","year":"2021","journal-title":"J Hosp Infect"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines and Variants Versus Efficacy, Effectiveness and Escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0364","article-title":"SARS-CoV-2 Seroprevalence in Germany","author":"Gornyk","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41467-021-20973-3","article-title":"Exploring Beyond Clinical Routine SARS-CoV-2 Serology Using MultiCoV-Ab to Evaluate Endemic Coronavirus Cross-Reactivity","volume":"12","author":"Becker","year":"2021","journal-title":"Nat Commun"},{"key":"B29","article-title":"Reduced Serum Neutralization Capacity Against SARS-CoV-2 Variants in a Multiplex ACE2 RBD Competition Assay","volume-title":"medRxiv","author":"Junker","year":"2021"},{"key":"B30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41467-021-27595-9","article-title":"Robust and Durable Serological Response Following Pediatric SARS-CoV-2 Infection","volume":"13","author":"Renk","year":"2022","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/srep03259","article-title":"Systematic Reference Sample Generation for Multiplexed Serological Assays","volume":"3","author":"Planatscher","year":"2013","journal-title":"Sci Rep"},{"key":"B32","volume-title":"R: A Language and Environment for Statistical Computing","year":"2021"},{"key":"B33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1521-4036(200001)42:1<17::AID-BIMJ17>3.0.CO;2-U","article-title":"The Nonparametric Behrens-Fischer Problem: Asymptotic Theory and A Small-Sample Approximation","volume":"42","author":"Brunner","year":"2000","journal-title":"Biometrical J"},{"key":"B34","unstructured":"lawstat: Tools for biostatistics, public policy, and law. R-package version 3.4\n            GastwirthJL\n            GelYR\n            Wallace HuiWL\n            LyubchichV\n            MiaoW\n            NoguchiK\n          2020"},{"key":"B35","first-page":"65","article-title":"A Simple Sequentially Rejective Multiple Test Procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scandinavian J Stat"},{"key":"B36","unstructured":"nlme: Linear and nonlinear mixed effects models. R-package version 3.1-155\n            PinheiroJ\n            BatesD\n            DebRoyS\n            SarkarD\n          2022"},{"key":"B37","unstructured":"WarnesGR\n            BolkerB\n            BonebakkerL\n            GentlemanR\n            HuberW\n            LiawA\n          Gplots: Various R Programming Tools for Plotting Data. R package version 3.1.1.2021"},{"key":"B38","unstructured":"EklundA\n            TrimbleJ\n          Beeswarm: The Bee Swarm Plot, an Alternative to Stripchart. R Package Version 0.4.0.2021"},{"key":"B39","unstructured":"Shared Mutations."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and Immunogenicity of Heterologous Versus Homologous Prime-Boost Schedules With an Adenoviral Vectored and mRNA COVID-19 Vaccine (Com-COV): A Single-Blind, Randomised, Non-Inferiority Trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet (London England)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00334-1","article-title":"Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals","volume":"9","author":"Behrens","year":"2020","journal-title":"Infect Dis Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.05.041","article-title":"Quantitative SARS-CoV-2 Anti-Spike Responses to Pfizer-BioNTech and Oxford-AstraZeneca Vaccines by Previous Infection Status","volume":"27","author":"Eyre","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1101\/2021.07.19.452771","article-title":"Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine Against SARS-CoV-2 Variants","volume-title":"bioRxiv","author":"Tada","year":"2021"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1101\/2021.10.26.21265397","article-title":"Two-Dose SARS-CoV-2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada","volume-title":"medRxiv","author":"Skowronski","year":"2021"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1101\/2021.07.26.21261140","article-title":"Higher Serological Responses and Increased Vaccine Effectiveness Demonstrate the Value of Extended Vaccine Schedules in Combatting COVID-19 in England","volume-title":"medRxiv","author":"Amirthalingam","year":"2021"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab938","article-title":"A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval","volume-title":"Clin Infect Dis","author":"Grunau","year":"2021"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","article-title":"Immunogenicity of Standard and Extended Dosing Intervals of BNT162b2 mRNA Vaccine","volume":"184","author":"Payne","year":"2021","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1101\/2021.09.17.21263532","article-title":"Strong Humoral Immune Responses Against SARS-CoV-2 Spike After BNT162b2 mRNA Vaccination With a 16-Week Interval Between Doses","volume-title":"Cell Host Microbe","author":"Tauzin","year":"2021"},{"key":"B50","article-title":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP, 2021): Assessment report Comirnaty. EMA\/707383\/2020 Corr1","year":""},{"key":"B51","article-title":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP, 2021): Assessment report COVID-19 Vaccine Moderna. EMA\/702084\/2021; EMEA\/H\/C\/005735","year":""},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150012","article-title":"Simultaneous Evaluation of Antibodies That Inhibit SARS-CoV-2 Variants via Multiplex Assay","volume":"6","author":"Lopez","year":"2021","journal-title":"JCI Insight"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently Neutralizing and Protective Human Antibodies Against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.21.21258528","article-title":"Correlates of Protection Against Symptomatic and Asymptomatic SARS-CoV-2 Infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"New Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc3539","article-title":"Antibody Signature Induced by SARS-CoV-2 Spike Protein Immunogens in Rabbits","volume":"12","author":"Ravichandran","year":"2020","journal-title":"Sci Trans Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7424","article-title":"Broad Neutralization of SARS-Related Viruses by Human Monoclonal Antibodies","volume":"369","author":"Wec","year":"2020","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9983","article-title":"Site-Specific Glycan Analysis of the SARS-CoV-2 Spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B61","doi-asserted-by":"publisher","first-page":"14991","DOI":"10.1038\/s41598-020-71748-7","article-title":"Analysis of the SARS-CoV-2 Spike Protein Glycan Shield Reveals Implications for Immune Recognition","volume":"10","author":"Grant","year":"2020","journal-title":"Sci Rep"},{"key":"B62","article-title":"Comparative Profiles of SARS-CoV-2 Spike-Specific Milk Antibodies Elicited by COVID-19 Vaccines Currently Authorized in the USA","volume-title":"medRxiv","author":"Fox","year":"2021"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.1101\/2021.07.01.450707","article-title":"Ad26.COV2.S Elicited Neutralizing Activity Against Delta and Other SARS-CoV-2 Variants of Concern","volume-title":"bioRxiv","author":"Jongeneelen","year":"2021"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2108829","article-title":"Durable Humoral and Cellular Immune Responses 8 Months After Ad26.COV2.S Vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1101\/2021.05.12.21257102","article-title":"Spike-Antibody Responses to ChAdOx1 and BNT162b2 Vaccines by Demographic and Clinical Factors (Virus Watch Study)","volume-title":"medRxiv","author":"Shrotri","year":"2021"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody Persistence Through 6 Months After the Second Dose of mRNA-1273 Vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.1101\/2021.09.27.21264163","article-title":"Four SARS-CoV-2 Vaccines Induce Quantitatively Different Antibody Responses Against SARS-CoV-2 Variants","volume-title":"medRxiv","author":"van Gils","year":"2021"},{"key":"B68","article-title":"Low-Dose mRNA-1273 COVID-19 Vaccine Generates Durable Memory Enhanced by Cross-Reactive T Cells","volume-title":"Science","author":"Mateus","year":"2021"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4509","article-title":"Adaptive Immune Determinants of Viral Clearance and Protection in Mouse Models of SARS-CoV-2","volume-title":"Sci Immunol","author":"Israelow","year":"2021"},{"key":"B70","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct Antibody and Memory B Cell Responses in SARS-CoV-2 Na\u00efve and Recovered Individuals Following mRNA Vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01410-w","article-title":"Impact of Vaccination on New SARS-CoV-2 Infections in the United Kingdom","volume":"27","author":"Pritchard","year":"2021","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.26882","article-title":"Trajectory of COVID-19 Vaccine Hesitancy Over Time and Association of Initial Vaccine Hesitancy With Subsequent Vaccination","volume":"4","author":"Siegler","year":"2021","journal-title":"JAMA Network Open"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067873","article-title":"Elapsed Time Since BNT162b2 Vaccine and Risk of SARS-CoV-2 Infection: Test Negative Design Study","volume":"375","author":"Israel","year":"2021","journal-title":"BMJ"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30699-X","article-title":"The Complexities of SARS-CoV-2 Serology","volume":"20","author":"Houlihan","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2113151","article-title":"Covid-19 Vaccine Effectiveness and the Test-Negative Design","volume":"385","author":"Dean","year":"2021","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001251","article-title":"A Test-Negative Design With Additional Population Controls Can Be Used to Rapidly Study Causes of the SARS-CoV-2 Epidemic","volume":"31","author":"Vandenbroucke","year":"2020","journal-title":"Epidemiology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.610688","article-title":"Humoral Responses and Serological Assays in SARS-CoV-2 Infections","volume":"11","author":"Galipeau","year":"2020","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.099","article-title":"Evaluation of Post-Introduction COVID-19 Vaccine Effectiveness: Summary of Interim Guidance of the World Health Organization","volume":"39","author":"Patel","year":"2021","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.828053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:42:47Z","timestamp":1644972167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.828053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2022.828053"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.828053","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.01.21266960","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"article-number":"828053"}}